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Severe acute respiratory syndrome (SARS) has raised
a global alert since March 2003. After its causative agent,
SARS-associated coronavirus (SARS-CoV), was con-
firmed, laboratory methods, including virus isolation,
reverse transcriptase–polymerase chain reaction (RT-
PCR), and serologic methods, have been quickly devel-
oped. In this study, we evaluated four serologic tests ( neu-
tralization test, enzyme-linked immunosorbent assay
[ELISA], immunofluorescent assay [IFA], and immunochro-
matographic test [ICT]) for detecting antibodies to SARS-
CoV in sera of 537 probable SARS case-patients with cor-
relation to the RT-PCR . With the neutralization test as a
reference method, the sensitivity, specificity, positive pre-
dictive value, and negative predictive value were 98.2%,
98.7%, 98.7%, and 98.4% for ELISA; 99.1%, 87.8%, 88.1%
and 99.1% for IFA; 33.6%, 98.2%, 95.7%, and 56.1% for
ICT, respectively. We also compared the recombinant-
based western blot with the whole virus–based IFA and
ELISA; the data showed a high correlation between these
methods, with an overall agreement of >90%. Our results
provide a systematic analysis of serologic and molecular
methods for evaluating SARS-CoV infection.
S
evere acute respiratory syndrome (SARS) is a new
infectious disease with clinical symptoms indistin-
guishable from atypical pneumonia at the early stage of ill-
ness (1). Because of its relatively high transmissibility and
mortality rate on infection, >8,400 SARS patients, includ-
ing 810 deaths, have been reported by China, Vietnam,
Hong Kong, Singapore, Canada, Taiwan, and other areas
worldwide from March to July 2003 (2). As of July 31, 668
probable SARS case-patients, including 71 deaths, were
reported to the Center for Disease Control, Taiwan (Center
for Disease Control–Taiwan) (3). With the close coopera-
tion of laboratories worldwide, the causative agent of
SARS was quickly identified as a new coronavirus species,
now referred to as SARS-associated coronavirus (SARS-
CoV) (4–6). With epidemiologic evidence, droplet and
close contact transmission are the major routes for the
spread of SARS (7). Suspected SARS patients need to be
quarantined and treated with intense care to minimize
transmission to others. Therefore, sensitive and specific
laboratory tests to differentiate SARS from other mild
atypical pneumonia must be developed to shorten the quar-
antine period for contacts with SARS patients and further
to contain SARS outbreaks.
Even though the RT-PCR is the most sensitive technique
to detect early SARS-CoV infection, the positive predictive
rate for probable SARS cases is only 37.5% according to
our data (Center for Disease Control–Taiwan). The other
reported probable SARS cases, therefore, still have to rely
on serologic diagnosis. We analyzed the results from
immunofluorescence assay (IFA), enzyme-linked
immunosorbent assay (ELISA), neutralization test, and
immunochromatographic test (ICT) to detect antibodies
against SARS-CoV in serum specimens of patients with
probable SARS in Taiwan. The results of neutralization
tests, ELISA, and IFA were highly correlated.
Materials and Methods
Specimens
According to World Health Organization (WHO) crite-
ria, a person seeking treatment after November 1, 2002,
with a history of high fever (>38°C), coughing, or breath-
ing difficulty, and having resided in or traveled to an area
with recent local transmission of SARS during the 10 days
before onset of symptoms was classified as a suspected
case-patient. A suspected case-patient with radiographic
evidence of infiltrates consistent with pneumonia or respi-
ratory distress syndrome on a chest x-ray was considered a
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*Center for Disease Control, Department of Health, Taiwan,
Republic of China probable case-patient (8). In the study, 3,367 throat swab
specimens from possible SARS patients reported to Center
for Disease Control-Taiwan were tested for SARS-CoV by
RT-PCR. Seven hundred and ninety-nine serum samples
from 537 probable case-patients, fulfilling WHO criteria
for probable SARS cases, were tested for antibodies to
SARS-CoV by neutralization test, IFA, ELISA, and ICT.
Of these patients, 262 had paired serum specimens, in
which the acute- and convalescent-phase serum specimens
were collected at day 1 to day 12 and at day 28 or more
after the onset of illness, respectively. In the other 275
patients, only a single serum specimen was collected dur-
ing their illness: 210 had the serum collected at the acute
phase or at the early convalescent phase from day 1 to day
20, and 65 were collected during the late convalescent
phase from day 28 to day 78 after the illness onset. 
RT-PCR
The primers and probes used for SARS-CoV detection
by RT-PCR and real-time RT-PCR were synthesized,
according to the recommendations of the Centers for
Disease Control and Prevention (CDC), Atlanta, Georgia,
USA(5,9). The viral RNAfrom the throat swab specimens
was extracted by the MagNA LC Pure and MagNA Pure
LC total nucleic acid isolation kit (Rouche, Mannheim,
Germany). After extraction, 5 µL of RNAextract was used
as the template in all PCR assays in 50-µL reaction vol-
umes containing 10 µL of 5X buffer, 2 µL enzyme mix,
2 µL deoxynucleoside triphosphate (dNTP), and 0.6 µM
each of sense and antisense primer. The reaction was sub-
jected to precycle condition at 50°C for 30 min, and 95°C
for 15 min. Forty cycles of amplification were then con-
ducted at 95°C for 30 s, 50°C for 40 s, and 72°C for 1 min.
For real-time quantitative RT-PCR assays, a 20-µL reac-
tion volumes containing 12 µL of HPA (human pneumo-
nia–associated coronavirus)-Coronavirus LC Master mix,
3 µLof HPA-Coronavirus LC Mg-Sol, and 0.5 µLof HPA-
Coronavirus LC internal control were thermal-cycled by a
Light Cycler (Rouche) at 50°C, for 10 min for RT reaction,
at 95°C for 10 min for denaturation, and followed by 45
cycles of amplification at 95°C for 2 s, 55°C for 12 s, and
72°C for 10 s. 
Neutralization Test
Serum specimens were tested for neutralizing activity,
according to the procedures described by Marx et al. (10),
with modifications. The neutralization titer was deter-
mined in Vero E6 cells. Briefly, the serum specimens from
patients with probable SARS were first incubated at 56°C
for 30 min. Then, 50 µL of serial twofold diluted serum
specimen, from 8-fold to 1,024-fold were added into equal
volume of culture medium containing SARS-CoV (50 tis-
sue culture infective dose [TCID50] on a 96-well microtiter
plate) and incubated at 37°C for 1 h. Finally, 100 µLo f
Vero E6 cells (2.5 x 105/µL) were added to each well of the
plate. Cultures were held at 37°C and 5% CO2 with daily
observations for cytopathic effect (CPE). On day 5, the
titer of antibody was calculated as the highest dilution that
CPE was completely inhibited on the well. The neutraliza-
tion test was carried out with each sample in duplicate
along with both positive and negative controls. The posi-
tive control serum specimens were taken from patients
with confirmed SARS in Taiwan, and the negative control
serum specimens were from healthy volunteers. If a sam-
ple showed a 4-fold difference or greater in titers in the
duplicated sample runs, it was judged as an invalid out-
come and had to be retested. A sample is considered to be
positive if its titer is >1:16 in the case of single serum
group, and at least a 4-fold increase in titers between the
acute- and convalescent-phase serum specimens in the
paired specimens group.
IFA
IFA testing was performed by using a diluted serum
specimen reacted against SARS-CoV-infected Vero E6
cells and uninfected Vero E6 cells. Vero E6 cells were
grown in minimum essential medium (MEM) containing
10% fetal bovine serum at 37°C. At a density of 80%, the
cells were infected with SARS-CoV (TCID50, 106/mL).
After CPE appeared, the cells were washed with 0.025%
trypsin and spotted on slides for IFA as previously
described (11). These slides were put in a closed heating
container until completely drying, then were fixed in ace-
tone for 15 min. 10 µL of 2-fold serial diluted serum start-
ing from 1:100 to 1:800 was placed onto each well of the
slide, and incubated at 37°C for 30 min. After being
washed twice with phosphate-buffered saline (PBS), for
5 min each, 10 µL of 1:100 diluted specific antihuman
gamma globulins labeled with FITC (Zymed) was added
onto each well, and incubated at 37°C for 30 min. After
washing twice with PBS, slides were observed under a flu-
orescence microscope. Criteria for a positive IFA result
included reactivity to infected cells. Asample with an anti-
body titer of 1:100 is positive. Sera that did not react to
infected cells were considered negative. If nonspecific
reactivity to both infected and uninfected cells were detect-
ed, the test was considered un-interpretable.
ELISA
An ELISA for the detection of coronavirus has been
described (12). In our study, the materials for the ELISAto
detect SARS-CoV antibodies were provided by CDC in
Atlanta. In brief, SARS-CoV Vero E6 cell lysates used as
antigens were added to the top half of the wells in the plate
overnight at 4°C. The Vero E6 cell lysates without SARS-
CoV used as control antigens were simultaneously added
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ing day, 100 µL of diluted serum (starting from 1:100 to
1:1,600) was added to both test and control wells. Then
each well of the plate was incubated at 37°C for 60 min.
After washing the plate 3 times with 250 µLof wash buffer
in each well, add 100 µL of conjugate dilution (1:4,000 of
goat anti-human immunoglobulin (Ig) A, IgG, and IgM) to
each well and incubate the plate at 37°C for 60 min. Again
after washing, 100 µL of the substrate (a 1:1 mixture of
2,2-azino-di [3-ethylbenzthiazoline] sulfonic acid [ABTS]
and hydrogen peroxide) were added to each wells, and
incubated at 37°C for 30 min. Place the plate on ELISA
reader, and read at 410 nm. A sample is positive if its
adjusted optical density (OD) value (OD of test – OD of
control) exceeds the mean plus 3 standard deviations of the
normal controls and its titer is >1:400. 
ICT
The ICT generally refers to a rapid chromatographic
technique based on a sandwich format using double anti-
gens or double antibodies (13). The SARS-CoV rapid test
we adopted is a newly developed immunogold-based ICT
device (Tyson Bioresearch, Inc., Taipei, Taiwan). The anti-
gen used in this test is a recombinant nucleocapsid (N) pro-
tein of SARS-CoV. The inside of the ICT device contains
a nitrocellulose strip, on top of which is a detection zone.
In the detection zone, the goat anti-mouse IgG and SARS-
CoV N protein have been immobilized separately onto a
control line and a test line. In the middle of the strip, the
mouse IgG and SARS-CoV N protein are to be coupled
respectively with some colloidal gold particles, which
serve as a detector. At the bottom are two wells for the
sample and the buffer, respectively. The ICT is carried out
following the manufacture’s instruction. Briefly, 15 µLo f
undiluted serum sample is added to the sample well, and
220 µL of testing buffer to the buffer well. When the sam-
ple contains specific antibodies to SARS-CoV, they will
react first with the antigen-gold complex. After lateral flow
along the membrane, a colored complex of antibodies-anti-
gen-gold will deposit on the test line containing the fixed
antigen. The red signal from the gold will gradually appear
on the test line and become visible by naked eye. A posi-
tive result will show two parallel lines; the upper one is the
control line, which shows that the device works fine and
the lower one is the test line, which indicates that the
serum sample contains SARS-CoV antibodies. In case of a
negative result, only red will be seen on the control line. If
red is found only at the test line or no lines are visible, the
test is invalid.
Western Blot
The preparation of recombinant proteins of SARS-CoV
and the procedures for Western blot assay have been
described recently (14). Briefly, the amplified gene prod-
ucts of SARS-CoV including N, M (membrane), and S
(spike), were gel purified and cloned into the pQE30
expression vector (Qiagen, Valancia, CA). The constructs
were then transformed into Escherichia coli JM109 cells
(Invitrogen, Carlsbad, CA). After induction by isopropyl-
β-D-thiogalactopyranoside, the cells were sonicated, and
the recombinant proteins were extracted with 1.5% sarco-
sine. Finally these recombinant proteins were bound by
BD TALON metal affinity resins (BD Biosciences, San
Jose, CA) and examined by 12% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis. The Western
blot assay was carried out to examine the pattern of anti-
body development against different recombinant proteins
of SARS-CoV. 
Results
Detection of Viral RNA of SARS-CoV by RT-PCR 
A total of 3,367 possible SARS patients were reported
to Center for Disease Control-Taiwan from March 10
through the end of July 2003. Of which, 668 were proba-
ble case-patients, 1,331 were suspected case-patients,
1,036 were rejected, and 332 case-patients were removed
from reporting (Table 1). Throat swabs were collected
from 590 of the 668 patients with probable cases. Of them,
221 had positive results on PCR, giving a positive rate of
37.5%. Throat swabs were also collected from 1,043 of the
1,331 patients with suspected cases. Of them, 38 had pos-
itive results by PCR, giving a positive rate of 3.6%. Figure
1 shows the PCR-positive rates of the throat swab speci-
mens taken from patients with probable SARS between
day 1 and day 13 after the illness onset. On the first day of
onset, RT-PCR detected positive results in 32% of patients
with suspected cases. The positive rates reached a peak of
50% to 60% on day 7 to day 10 and declined thereafter.
However in a few specimens, virus RNAwas still detected
on day 18, day 20, and day 38 after illness onset (data not
shown). 
Detection of Antibodies to SARS-CoV 
in Probable SARS Patients 
Figure 2 shows when antibodies to SARS-CoV
appeared during the infection. Although in samples from
10% (14/138) of the probable case-patients, antibodies to
SARS-CoV could be detected during the acute phase of ill-
ness (day 1 to day 7) by neutralization test, IFA, or ELISA,
antibodies against SARS-CoV developed in most at the
late convalescent stage. The positive rate of antibodies to
SARS-CoV was raised to 50% at 3 weeks after illness
onset and reached to a peak of over 70% at 10 weeks after
onset. The overall antibody-positive rate was 54.2%
(254/469).
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Of the total 537 probable SARS case-patients, 469 had
been tested for the antibody response to SARS-CoV by
neutralization test, ELISA, and IFA in parallel, but only
244 patients were tested by ICT. With neutralization tests
as a reference method, the overall characteristics of the
evaluated methods, including ELISA, IFA, and ICT, are
given in Table 2. For ELISA, the sensitivity was measured
at 98.2%. Of the 224 serum specimens, which tested posi-
tive with neutralization test, 4 gave negative responses
with ELISA. The specificity, positive predictive value, and
negative predictive value were 98.7%, 98.7%, and 98.4%,
respectively. For IFA, the sensitivity was evaluated at
99.1%. Two serum samples, which had been positive in
neutralization test, were negative with IFA. The specifici-
ty, positive predictive value, and negative predictive value
were of 87.8%, 88.1%, and 99.1%, respectively. The speci-
ficity of the ICT was calculated to be 98.2%; however, its
sensitivity (33.6%) was low, leading to a negative predic-
tive value of 56.1%. In the total of 245 negative neutraliza-
tion tests, 3 positive results were detected with ELISA, 30
positive with IFA, and 2 positive with ICT tests. These
35 specimens were taken from 31 patients, in which two
positive PCR results were found.
Cross-Reactions with the Non-SARS Panel
Ten normal serum samples from healthy volunteers
tested negative for antibodies against SARS-CoV by neu-
tralization test, IFA, ELISA, and ICT. In addition, 24
serum samples from patients with other diseases were used
as a specificity panel to analyze whether these assays
showed any cross reactions with SARS-CoV. These
patients were definitely confirmed as non-SARS-
CoV–associated diseases. As shown in Table 3, no positive
results were detected to these serum specimens, and the
measurements of specificity were all 100% for the neutral-
ization test, ELISA, IFA, and ICT. 
Values of RT-PCR and Neutralization Test 
Table 4 compares results of the RT-PCR and the neu-
tralization test in specimens from probable SARS case-
patients. In this comparison, throat swab specimens from
381 probable SARS case-patients were used for RT-PCR,
and their convalescent-phase serum specimens, collected
on day 28 or longer after illness onset, were tested with
neutralization test. Of the 207 cases, which were positive
by neutralization test, 145 were tested positive with RT-
PCR. The sensitivity, specificity, positive predictive value,
and negative predictive value of RT-PCR compared with
results with neutralization test were of 52.2%, 78.7%,
74.5%, and 58.1%, respectively.
Laboratory Confirmation Rate for
Probable SARS Case-Patients
Table 5 shows the laboratory confirmation rate of prob-
able SARS cases in Taiwan. With 469 probable case-
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Table 1. Positive rates of RT-PCR for SARS-CoV in reported SARS cases in Taiwan   
Classification of reported cases  Case no.  Specimens collected
a  No. PCR (+)  Positive rate (%) 
Probable   668  590  221  37.5 
Suspected   1,331  1,043  38  3.6 
Ruled out  1,036  907  7  0.8 
Reporting cancelled  332  229  1  0.4 
Total   3,367  2,769  267  9.6 
aThroat swab specimens were used for RT-PCR (reverse transcriptase–polymerase chain reaction). SARS-CoV, severe acute respiratory syndrome–associated 
coronavirus. 
Figure 1. Polymerase chain reaction–positive rates of throat swab
specimens collected on different days from probable SARS cases.
If a patient had two or more specimens, the patient was only
counted once.
Figure 2. Antibody-positive rate of serum specimens collected on
different days from probable SARS case-patients. If a patient had
















.patients tested, the positive rate of RT-PCR is 33.7%
(158/469). These patients had been also tested for the anti-
body response to SARS-CoV by neutralization test,
ELISA, and IFA, but only 244 were tested by ICT. The
seropositive rate for ELISA, IFA, neutralization test, and
ICT were 47.5% (223/469), 57.7% (252/469), 47.8%
(224/469), and 16.8% (41/224), respectively. If these
results were combined with existing RT-PCR results, the
laboratory confirmation rates of probable SARS cases
went up to 57.4% (269/469), 63.3% (297/469), 57.8%
(271/469), and 42.4% (103/244), respectively.
Recombinant Antigens for SARS Serologic Diagnosis
As discussed above, all the neutralization tests, ELISA,
and IFA are based on the whole viral extracts of SARS-
CoV. Therefore, antigens for these serologic tests must be
prepared in the biosafety level 3 laboratory. To provide a
convenient tool and decrease the risk of infection, a
Western blot with several SARS-CoV recombinant pro-
teins was developed and evaluated. Cloned peptides carry-
ing epitopes can be produced on a large scale and with an
acceptable degree of purity. Table 6 shows the comparison
of recombinant protein-based Western blot with whole
virus-based IFA, and ELISA. Ninety-five serum samples
were used in this comparison. The sensitivities, specifici-
ties and overall agreements of Western blot were 91.3%,
89.88%, and 90.5%, compared with IFA results; 97.6%,
88.8%, and 92.6%, compared with ELISA results. 
Discussion
The study shows that in the first 2-week period after
onset of SARS, RT-PCR is the most sensitive method of
detecting the virus RNA, and the positive rate is the high-
est. However, during the convalescent phase of the disease,
detecting antibodies in serum specimens is more important
than detecting viral RNA. Four serologic diagnostic meth-
ods, including neutralization test, ELISA, IFA, and ICT
were each evaluated and compared for antibody responses
to SARS-CoV infection, in which the neutralization test
was held as a reference method. The specificity of these
methods is extremely good (100%), since no cross-reac-
tions were detected with a non-SARS disease panel. 
However, some variations in sensitivity, positive pre-
dictive value, and negative predictive value were found
among these methods. As shown in Table 2, ELISAresults
were highly correlated with results from the reference
method, the neutralization test. The measured performance
of ELISA was so outstanding, with the sensitivity, speci-
ficity, positive predictive value, and negative predictive
value levels exceeding 98%, that ELISA was chosen as a
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Table 2. Specificity, sensitivity, positive and negative predictive values of the tests evaluated for the serodiagnosis of SARS, in 
comparison to the neutralization test
a,b 
  Neutralization test  Performances of methods evaluated 
Method  Results  No.  Positive  Negative  Sensitivity  PPV  Specificity  NPV 
Positive  223  220  3  ELISA 
Negative  246  4  242 
98.2%  98.7%  98.7%  98.4% 
Positive  252  222  30  IFA 
Negative  217  2  215 
99.1%  88.1%  87.8%  99.1% 
Positive  46  44  2  ICT
c 
Negative  198  87  111 
33.6%  95.7%  98.2%  56.1% 
aN = 469. 
bSARS, severe acute respiratory syndrome; PPV, positive predictive value; NPV, negative predictive value; ELISA, enzyme-linked immunosorbent assay; IFA, 
immunofluorescent assay; ICT, immunochromatographic test. 
cOnly 244 serum samples were used for immunochromatographic test assay. 
Table 3. Specificity of the tests evaluated for the serodiagnosis of SARS, in comparison to the neutralization test with regards to 
samples which tested positive for other diseases
a,b 
Pathogen  Parameter  Number  Positive  Negative  Positive  Specificity  Positive  Specificity  Positive  Specificity 
Hepatitis B virus  HBs IgM  3  0  3  0  100%  0  100%  0  100% 
Hepatitis C virus  IgM  3  0  3  0  100%  0  100%  0  100% 
Adenovirus  Total Ab  1  0  1  0  100%  0  100%  0  100% 
Influenza A virus  Total Ab  3  0  3  0  100%  0  100%  0  100% 
Influenza B virus  Total Ab  1  0  1  0  100%  0  100%  0  100% 
Dengue virus  IgM  2  0  2  0  100%  0  100%  0  100% 
JEV  IgM  1  0  1  0  100%  0  100%  0  100% 
Hantavirus  Total Ab  1  0  1  0  100%  0  100%  0  100% 
Chlamydia pneumoniae  IgM  4  0  4  0  100%  0  100%  0  100% 
Mycoplasma pneumoniae    IgM  4  0  4  0  100%  0  100%  0  100% 
Streptococcus pneumoniae  Total Ab  1  0  1  0  100%  0  100%  0  100% 
Total non-SARS pathogens  24  0  24  0  100%  0  100%  0  100% 
aSARS, severe acute respiratory syndrome; ELISA, enzyme-linked immunosorbent assay; IFA, immunofluorescent assay; JEV, Japanese encephalitis virus; HB, hepatitis 
B; AB, antibody; Ig, immunoglobulin. 
bN = 469 confirmation alternative. In the case of IFA, both the sen-
sitivity and negative predictive value levels were above
99%; however, the specificity of 87.8% implies that IFA
may cause false-positive problems. Therefore, a weak pos-
itive IFA result should be retested by a neutralization test
or ELISA. The ICT, though simple and quick to perform,
is lacking in adequate sensitivity in our evaluation.
Therefore, it was not a reliable test for detecting of anti-
bodies to SARS-CoV.
Since the neutralization test, ELISA, and IFA all use
whole virus particles as the antigen, for safety reasons the
preparation of SARS-CoV antigen must be conducted in a
biosafety level 3 laboratory, which will prevent these test
methods from being widely applied. Therefore, the trend
in method development may lead toward the manufactur-
ing of antigens with certain recombinant proteins. In this
study, we compared a recombinant-based Western blot
with the whole virus-based IFA and ELISA, and the data
showed a high degree of correlation between these meth-
ods, with an overall agreement above 90% (Table 6).
Thus, using these recombinant antigens may become a
much safer alternative to detect antibodies against SARS-
CoV. 
Eight PCR-positive specimens were found in the group
of the ruled out and group of those that were reported can-
celed (Table 1), and they were selected to test for antibod-
ies to SARS-CoV by using acute-phase serum samples
between day 1 and day 4 after the illness onset. However,
no positive result was found by any of the IFA, ELISA,
and neutralization test. Since no convalescent-phase serum
specimens were collected from those patients, we do not
know the negative results are truly negative or just result-
ed from the timing of gathering specimens when no anti-
bodies were produced. Moreover, another 95 samples from
the ruled-out category had been tested with ELISA, but no
positive results were found. In addition, 283 specimens
from 1,036 case-patients with suspected SARS were also
assayed with ELISA and the neutralization test. Of them,
45 were positive with a positive rate of 15.9% (45/283).
Among the 35 PCR-positive specimens in the suspected
SARS category, 10 were also positive in detection of anti-
bodies to SARS-CoV. 
Finally, in this study, the overall antibody positive rate
for probable SARS patients was 54.2%. This rate was
much lower than that reported in Hong Kong, which
showed that the IgG seroconversion to SARS coronavirus
was as high as 93% (70/75) at day 28 after the illness onset
(15). This difference may come from some different cir-
cumstances between Hong Kong and Taiwan. In the SARS
outbreak of Hong Kong, the index case-patient and the
infectious source leading to the outbreak were quite clear,
and 75 patients were admitted to the same hospital within
4 days. From the epidemiologic point of view, therefore,
the SARS outbreak was a typical cluster outbreak. In
Taiwan, the samples from probable SARS case-patients
were collected from over 50 hospitals between March and
June 2003. Some might not have been true SARS patients
but were reported as probable SARS cases. This result is
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Table 4. Specificity, sensitivity, positive and negative predictive values of the RT-PCR for the diagnosis of SARS, in comparison to the 
neutralization test with convalescent-phase serum specimens
a 
  Neutralization test  Performances of methods evaluated 
Method  Results  No.  Positive  Negative  Sensitivity  PPV
b  Specificity  NPV
b 
Positive  145  108  37  52.2%  74.5%      RT-PCR 
Negative  236  99  137      78.7%  58.1% 
aSARS, severe acute respiratory symptoms; RT-PCR, reverse transcriptase–polymerase chain reaction; PPV, positive predictive value;  NPV,  negative  predictive  value. 
bThe serum specimens of 28 days and more after the illness onset in probable SARS case-patients were tested in this comparison. 
Table 5. Laboratory confirmation rate in probable SARS cases, in combination of RT-PCR with different serologic methods
a 
Results  ELISA  IFA  Neutralization test  ICT 
PCR (+)  33.7% (158/469)  33.7% (158/469)  33.7% (158/469)  35.7% (87/244) 
Antibody (+)  47.5% (223/469)  57.7% (252/469)  47.8% (224/469)  16.8% (41/244) 
PCR (+) or antibody (+)  57.4% (269/469)  63.3% (297/469)  57.8% (271/469)  42.4% (103/244) 
aSARS, severe acute respiratory syndrome; ELISA, enzyme-linked immunosorbent assay; IFA, immunofluorescent assay; ICT, immunochromatographic test; PCR, 
polymerase chain reaction. 
Table 6. Comparison of recombinant protein–based Western blot with whole virus–based IFA and ELISA
a 
  IFA  ELISA 
Method  Results  Number  Positive  Negative  Sensitivity  Specificity 
Overall 
agreement




Western blot  Positive  47  42  5  91.3%  89.8%  90.5%      97.6%  88.8%  92.6% 
  Negative  48  4                   
aIFA, immunofluorescent assay; ELISA, enzyme-linked immunosorbent assay. 
bSum of the number of true positives and true negatives divided by total serum samples. likely due to the policy that suspicious SARS cases were to
be reported to local health agency within 24 hours in
Taiwan or the clinician who attended the patients would
have been fined. In September 2003, according to the
WHO criteria and the laboratory data, 346 patients were
reclassified as probable SARS patients by the Center for
Disease Control–Taiwan, and these data were readily
accepted by WHO on September 26, 2003 (16). With this
new classification, the positive rate of antibodies to SARS-
CoV in probable SARS patients in Taiwan was increased
to 86.6% (227/262), by using the serum samples on day 28
or beyond after the onset of illness. These rates are closer
to, though still lower than, rates from Hong Kong. Samples
from the remaining 322 cases, excluded from the category
of probable SARS cases, may have to be tested for other
pathogens, such as Mycoplasma pneumoniae, Chlamydia
pneumoniae, and human metapneumovirus to clarify a
diagnosis.
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